U.S. abortion opponents are increasingly frustrated with the lack of action by President Donald Trump's administration to stem the flow of abortion pills prescribed online that they view as undermining state abortion bans.
A court ruling this week in a lawsuit the Louisiana attorney general brought against Trump's Food and Drug Administration cast a spotlight on the simmering tension. The judge said the state has a strong case while declining to block
telehealth prescriptions to the pill mifepristone for now.
Anti-abortion groups are pushing the FDA to move faster with a review that they hope will result in restrictions on the abortion pill mifepristone, including blocking its prescribing via telehealth platforms. The administration says the work takes time.
The groups have focused mostly on the health agency and not the Republican president whose three U.S. Supreme Court appointees were instrumental in the 2022 ruling that overturned Roe v. Wade and allowed the state bans in the first place. But the administration's requests in the Louisiana lawsuit and similar ones elsewhere to delay rulings until it finishes a review have sparked anger for some activists.
“The stall tactics are beyond frustrating,” Kristi Hamrick, a spokesperson for Students for Life of America, said in an interview. Hamrick said the administration could also block the pills from being mailed by changing its interpretation of a 19th century law and enforcing it.
U.S. District Judge David Joseph, who was nominated to the bench by Trump, gave a mixed ruling Tuesday in a case brought by Louisiana Attorney General Liz Murrill and a woman who says her boyfriend coerced her into taking mifepristone to end a pregnancy.
Their overall aim is to roll back FDA rules that have made the pills more accessible. Murrill, like officials in other states that have filed similar lawsuits, contends that the availability of the pills via online providers takes the teeth out of the bans in the 13 states that bar abortion at all stages of pregnancy, with limited exceptions.
Surveys of abortion providers have suggested that its availability through telehealth is a reason the number of abortions in the U.S. has not dropped since the overturn of Roe. While state abortion bans include prohibitions on abortion using the pills, some Democratic-controlled states have adopted laws that seek to protect medical providers who prescribe them over telehealth and mail the pills to states with bans. Those so-called shield laws are being tested through civil and criminal cases.
In the Louisiana case, Joseph declined to grant Murrill's request to block telehealth prescriptions to the pills while the case moves through the courts. But he said he could do that eventually and the plaintiffs in the case are likely to succeed on the merits of their arguments because the state has demonstrated it's suffered “irreparable harm.”
He also ordered the FDA to report to him within six months on the status of its review of the drug.
On Wednesday, Murrill filed a notice that she's taking the case to the U.S. 5th Circuit Court of Appeals in hopes of forcing faster action.
Family Research Council President Tony Perkins, an influential conservative voice who is also a former Louisiana lawmaker, applauded Murrill's step.
He said people he meets are often shocked to learn that the number of abortions has not dropped since the 2022 Supreme Court ruling.
“Bewilderment sets in,” he said. “We’re already seeing an enthusiasm gap between the parties. What the Republicans do not need is a dampening of enthusiasm in their base.”
He's hoping the administration will restrict abortion pills rather than risk losing support from conservative, anti-abortion voters in November's midterm elections.
Other groups are being more cautions.
Madison LaClare, director of federal government affairs at National Right to Life, said her group trusts the administration to review mifepristone. Marjorie Dannenfelser, president of SBA Pro-Life America, avoided harsh words for the president: “The Trump-Vance administration has an important opportunity right now to prioritize women’s safety,” she said in a statement.
Still, recent electoral results suggest that voters seeking to keep abortion available have the political momentum. Since Roe was overturned, abortion has on the ballot directly in 17 states. Voters have sided with the abortion-rights side in 14 of those questions.
“There seems to be an emerging consensus in the country that people don’t want to ban abortion,” said Rachel Rebouche, a professor at the University of Texas School of Law who studies abortion.
In a statement Wednesday in response to questions from The Associated Press, the FDA said it's reviewing the safety of mifepristone, “including the collection of robust and timely data, evaluation of data integrity, and implementation of the analyses, validation, and peer-review.”
After that, the agency said, it will decide whether to make changes to the rules about how the drug can be prescribed.
It said this kind of study can take a year or more to complete by academics but the agency is trying to move faster than that. A spokesperson did not answer questions about when the work began.
Mifepristone has been a political priority for anti-abortion activists and their allies in Congress since Trump returned to office last year. In his January 2025 confirmation hearing, Health and Human Services Secretary Robert F. Kennedy Jr. was repeatedly asked about the drug by Republican lawmakers and said the president had requested a safety review.
Frustration over signs that the FDA isn't prioritizing curbing abortions flared last fall when the FDA approved an additional generic version of mifepristone.
The drug is most often used for abortion in combination with another drug, misoprostol.
Mifepristone was approved in 2000 as a safe and effective way to end early pregnancies.
Because of rare cases of excessive bleeding, the FDA initially imposed strict limits on who could prescribe and distribute the pill — only specially certified physicians and only after an in-person appointment where the person would receive the pill.
Both those requirements were dropped during the COVID years. At the time, FDA officials said that after more than 20 years of monitoring mifepristone use, and reviewing dozens of studies involving thousands of women, it was clear that women could safely use the pill without direct supervision.
